Search / Trial NCT00000373

Treatment of Obsessive-Compulsive Disorder

Launched by UNIVERSITY OF FLORIDA · Nov 2, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

Adolescence Adult Antipsychotic Agents Dopamine Antagonists Female Fluvoxamine Haloperidol Human Male Middle Age Obsessive Compulsive Disorder Placebos Serotonin Uptake Inhibitors Tourette Syndrome Tryptophan Drug Combinations Antipsychotic Agents *Therapeutic Use Fluvoxamine *Therapeutic Use Haloperidol *Therapeutic Use Obsessive Compulsive Disorder *Drug Therapy Obsessive Compulsive Disorder Physiopathology Serotonin Uptake Inhibitors *Therapeutic Use

ClinConnect Summary

To advance the neurobiology and treatment of obsessive-compulsive disorder (OCD) by focusing on Tourette's Syndrome (TS)-spectrum OCD as a possible homogeneous form of OCD, and investigating the relevance of intact 5-hydroxytryptamine (5-HT) function to the mechanism of anti-OC drug action. The validity of TS-spectrum OCD as a distinct subtype is assessed using a detailed clinical, family, drug treatment response profile in adult OCD patients.

In Study I, patients are divided prospectively into 2 putative subtypes (TS-spectrum and non-TS-spectrum OCD) on the basis of clinical history and d...

Gender

ALL

Eligibility criteria

  • Inclusion criteria required that subjects, ages 14-70 years, have at least a 1-year duration of a current Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) principal diagnosis of OCD. Furthermore, the OCD had to be defined by a rating of "moderate" or greater on the global severity item of the Clinical Global Impressions (CGI) scale and have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of 19 or greater.
  • Exclusion criteria included primary depression, schizophrenia, or other psychotic disorders; active bipolar disorder; abuse of alcohol or other significant substance within 6 months; increased risk of seizures or history of neurosurgery, encephalitis, or significant head trauma; or a significant medical condition, such as heart, liver, or renal disease. Subjects with an intelligence quotient of less than 80 as determined with the Kaufman Brief Intelligence Test (Kaufman and Kaufman 1990) were excluded.

Trial Officials

Wayne Goodman, MD

Principal Investigator

University of Florida

About University Of Florida

The University of Florida, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials. With a focus on enhancing patient outcomes and exploring new therapeutic avenues, the university leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct rigorous research across a variety of medical fields. Committed to ethical standards and patient safety, the University of Florida fosters collaboration among researchers, healthcare professionals, and community stakeholders to translate scientific discoveries into impactful clinical applications.

Locations

Gainesville, Florida, United States

Jacksonville, Florida, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials